Deferred Royalty Obligation related to the Sale of Future Royalties (Tables)

3 Months Ended

Mar. 31, 2024

Deferred Royalty Obligation [Abstract]

Schedule of Royalty Obligation transaction

The following table shows the activity of the deferred royalty obligation for the three months ended March 31, 2024:

	March 31, 2024
	(in thousands)
Liability related to sale of future Vaxcyte royalties - beginning balance	$	149,114
Non-cash interest expense associated with the sale of future Vaxcyte royalties		7,184
Amortization of issuance costs		167
Liability related to the sale of future Vaxcyte royalties - ending balance	$	156,465